Edition:
United Kingdom

Manojna Maddipatla

Ardelyx drug reduces elevated phosphate levels, late-stage study shows

03 Dec 2019

Ardelyx Inc's experimental drug has shown promise in a late-stage study as a standalone therapy to reduce elevated blood phosphate levels in patients with chronic kidney disease (CKD), the drugmaker said on Tuesday.

UPDATE 2-China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

14 Nov 2019

Nov 14 The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's strategy of largely using data from trials held outside the United States to file for approval.

FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug

14 Nov 2019

Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes.

Solid Biosciences shares plummet as gene therapy trial halted again

12 Nov 2019

Shares in Solid Biosciences Inc plunged 71% on Tuesday after a trial testing its gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.

New tuberculosis treatment for developing countries to cost $1,040

28 Oct 2019

A newly approved three-drug treatment for tuberculosis will be available in 150 countries including India and South Africa, priced at $1,040 for a complete regimen, more than twice the cost proposed in the past by advocacy groups for other treatments.

CORRECTED-New tuberculosis treatment for developing countries to cost $1,040

28 Oct 2019

Oct 28 A newly-approved three-drug treatment for tuberculosis will be available in 150 countries including India and South Africa, priced at $1,040 for a complete regimen, more than twice the cost proposed in the past by advocacy groups for other treatments.

Big U.S. retailers pull 22-ounce J&J baby powder off shelves after recall

25 Oct 2019

Four major U.S. retailers, including Walmart and Target Corp , are removing all 22-ounce bottles of Johnson & Johnson's baby powder from their stores, following the healthcare conglomerate's recall last week of some bottles due to possible asbestos contamination. | Video

Vertex prices cystic fibrosis combo treatment at $311,000-per-year

21 Oct 2019

Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis (CF) at $311,503 per year, after winning early U.S. approval on Monday.

World News